Abstract: The present disclosure provides an array substrate and a display panel. The array substrate includes a wiring layer, and a non-wiring layer located on a bottom portion of the wiring layer. The non-wiring layer includes a first film layer and a second film layer, which are sequentially stacked in a direction away from the wiring layer. A refractive index of the second film layer is smaller than a refractive index of the first film layer.

Abstract: An antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune-related disorders, such as tumors.

Abstract: The present disclosure provides an array substrate and a display panel. The array substrate includes a wiring layer, and a non-wiring layer located on a bottom portion of the wiring layer. The non-wiring layer includes a first film layer and a second film layer, which are sequentially stacked in a direction away from the wiring layer. A refractive index of the second film layer is smaller than a refractive index of the first film layer.

Abstract: A method for the preparation of a dense HfC(Si)—HfB2 composite ceramic. hafnium oxide powders, nano-sized carbon black and silicon hexaboride powders are mixed in a molar ratio of (1-10):(1-20):(1-5) to obtain a powder mixture. The powder mixture is subjected to ball milling, dried and transferred to a graphite mold for spark plasma sintering. In this way, an in-situ carbon-boron reduction reaction and the sintering densification are completed in one step, and the obtained HfC(Si)—HfB2 composite ceramic has a density of 94.0%-100% and uniformly dispersed grains.

Abstract: The present application relates to an ion transmission device, more particularly, to a device and method for generating, storing and transmitting positive and negative ions. The device includes a wire electrode, a perforated insulating board, a tensioning device, an axial field electrode and an ion source for providing ions. The generated positive and negative ions are respectively stored on two ends of a cavity by the device; and the positive or negative ions are led out as needed. The utilization efficiency of positive and negative ions, as well as sensitivity, are greatly improved by the device.

Abstract: A position monitoring system is provided. The position monitoring system includes: a first support, configured to be movably connected to a patient supporting device; at least one first marking component, disposed at a portion to be treated of a patient; at least one second marking component, disposed at a preset position; a movement monitoring device, disposed on the first support and configured to monitor a displacement of the first marking component relative to the second marking component; and a control device, connected to the movement monitoring device and configured to determine whether a position of the portion to be treated of the patient is moved according to the displacement monitored by the movement monitoring device.

Abstract: A method for the preparation of a dense HfC(Si)—HfB2 composite ceramic. hafnium oxide powders, nano-sized carbon black and silicon hexaboride powders are mixed in a molar ratio of (1-10):(1-20):(1-5) to obtain a powder mixture. The powder mixture is subjected to ball milling, dried and transferred to a graphite mold for spark plasma sintering. In this way, an in-situ carbon-boron reduction reaction and the sintering densification are completed in one step, and the obtained HfC(Si)—HfB2 composite ceramic has a density of 94.0%-100% and uniformly dispersed grains.

Abstract: Use of carrimycin in Mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in Mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated Mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle Bacillus infected diseases are expected to be developed.

Abstract: The present application discloses a flexible display panel and a display device, including a first edge and a second edge perpendicular to each other, and a first display unit and a second display unit symmetrical to each other. The first display unit is not parallel to the first edge at a preset angle and is connected to the second display unit by signal wires. The signal wires include a first line, a second line, and a third line. The first line is connected to the first display unit and is parallel to the first display unit. The second line is connected to the second display unit and is parallel to the second display unit. Two ends of the third line are respectively connected to the first line and the second line in a zigzag shape. Bending resistance of the flexible display panel of the present application is increased.

Abstract: Disclosed are an mTOR inhibitor, a pharmaceutical composition and use thereof. The mTOR inhibitor includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III. The pharmaceutical composition also includes a drug for treating and/or preventing diseases related to the mTOR pathway as a second active ingredient. The mTOR inhibitor has obvious inhibiting effect on cells of diseases related to mTOR pathway, and is used for preparing drugs for treating and/or preventing diseases related to the mTOR pathway.

Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Abstract: A medicament for preventing and/or treating a disease is disclosed, the disease is Alzheimer's disease, diabetes or senility; and the medicament includes a first active ingredient, and the first active ingredient includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III.

Abstract: Disclosed are a medicament comprising isovaleryl spiramycin I, II and/or III, and use of isovaleryl spiramycin I, II and/or III in manufacturing medicament for treating and/or preventing tumor and the medicament.

Abstract: The present application relates to an ion transmission device, more particularly, to a device and method for generating, storing and transmitting positive and negative ions. The device includes a wire electrode, a perforated insulating board, a tensioning device, an axial field electrode and an ion source for providing ions. The generated positive and negative ions are respectively stored on two ends of a cavity by the device; and the positive or negative ions are led out as needed. The utilization efficiency of positive and negative ions, as well as sensitivity, are greatly improved by the device.

Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Abstract: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.

Abstract: A source switching apparatus comprises a plurality of collimators, a switch carrier, a source carrier. The switch carrier is assembled with a plurality of shielding elements regularly distributed thereon. The source carrier is assembled with a plurality of radiation sources regularly distributed thereon. The collimator, the switch carrier, and the source carrier are connected to one another via respective driver, to rotate with common angular velocity or in a differential movement, and wherein in the case when the differential movement is holding, a angle difference is formed between the switch carrier and the source carrier.

Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.

Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, comprising the steps of: (a) constructing a recombinant plasmid comprising a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I—producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively comprising a single gene ist.

Abstract: A sunshine angle adjustable solar energy electric wheel chair, a solar energy cell is mounted on the electric wheel chair so as to charge up a storage battery, left and right horizontal pipes for mounting the cell are supported by four lifted stand pipes, the height of the lifted stand pipes is adjusted, i.e. the sunshine angle may be adjusted at six azimuth, so that the charging current is maximized.